General considerations for lung function testing

Miller, Martin; Crapo, Robert O.; Hankinson, John; Brusasco, Vito; Burgos, Felip; Casaburi, Richard; Coates, Allan L.; Enright, P.; Grinten, C.P.M. van der; Gustafsson, Per; Jensen, Robert L.; Johnson, Douglas C.; MacIntyre, Neil R.; McKay, Roy T.; Navajas, Daniel; Pedersen, Ole F.; Pellegrino, Riccardo; Viegi, Giovanni; Wanger, Jack

doi:10.1183/09031936.05.00034505

Cited by 1,708 publications

(1,175 citation statements)

References 84 publications

Supporting

Mentioning

1,091

Contrasting

Unclassified

Order By: Relevance

“…Pulmonary function testing was performed with automated equipment (Master Screen Body PFT Jaeger, Würtzburg, Germany) using the current recommendations of the ATS/ERS Task Force on standardisation of pulmonary function tests [5,10,11].…”

Section: Article In Pressmentioning

confidence: 99%

A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD

Cazzola

Rogliani

Curradi

et al. 2009

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

show abstract

Section: Article In Pressmentioning

confidence: 99%

A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD

Cazzola

Rogliani

Curradi

et al. 2009

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

show abstract

“…Visit 1 could occur on the same day as screening and it was recommended to be completed within 14 from medical records. Measurement of pulmonary function was obtained using spirometry equipment according to ATS recommendations [13]. For FEV 1 and FVC, the largest values from three acceptable efforts (maximum of eight attempts) were recorded, even if they did not come from the same effort.…”

Section: Study Visits and Assessmentsmentioning

confidence: 99%

Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study

Albers

Müllerová²,

Gunsoy³

et al. 2017

Journal of Asthma

View full text Add to dashboard Cite

Objectives: Severe asthma comprises several distinct phenotypes. Consequently, patients with severe asthma can be eligible for more than one biologic treatment targeting Th2 inflammation, such as anti-interleukin (IL)-5 and anti-immunoglobulin (Ig) E. The objective of this study was to describe treatment eligibility and overlap in treatment eligibility for mepolizumab (anti-IL-5), omalizumab (anti-IgE) and reslizumab (anti-IL-5) in patients with severe asthma, who were recruited from clinical practice. Methods: This cross-sectional, single-visit, observational study in six countries enrolled patients with severe asthma (defined by American Thoracic Society/European Respiratory Society guidelines). Assessable patients were analysed as a total cohort and a sub-cohort, who were not currently receiving omalizumab. Treatment eligibility was defined according to the local prescribing information or protocol-defined inclusion/exclusion criteria. Patients currently receiving omalizumab were automatically categorised as omalizumab-eligible. Results: The total cohort comprised 670 patients who met the analysis criteria, of whom 20% were eligible for mepolizumab, 31-41% were eligible for omalizumab (depending on eligibility criteria used), and 5% were eligible for reslizumab. In patients not currently receiving omalizumab (n = 502), proportions eligible for each biologic were similar (mepolizumab: 20%, reslizumab 6%) or lower (omalizumab 7-21%) than those for the total cohort. Overlap in treatment eligibility varied; in mepolizumab-eligible patients not currently receiving omalizumab (n = 101), 27-37% were omalizumab-eligible and 18% were reslizumab-eligible. Conclusions: Treatment eligibility for mepolizumab and omalizumab was higher than that for reslizumab. Although there was some overlap in treatment eligibility, the patient groups eligible for treatment with anti-IL-5 or anti-IgE therapies were often distinct, emphasising the different phenotypes and endotypes in severe asthma.

show abstract

“…Exclusion criteria for the spirometric tests were: recent abdominal or ocular surgery, cardiovascular disorders, blood pressure higher than 180/100 mm Hg, untreated glaucoma and ocular lesions or pain during test performance (Miller et al, 2005).…”

Section: Study Subjectsmentioning

confidence: 99%

Total dietary antioxidant capacity and lung function in an Italian population: a favorable role in premenopausal/never smoker women

et al. 2011

View full text Add to dashboard Cite

Background/Objectives: Antioxidant-rich foods may favorably influence lung function. We examined possible associations between the total dietary antioxidant capacity (TAC) and pulmonary function in a healthy Italian population. Subjects/Methods: Until May 2009, 22 300 persons were randomly recruited from the general population in the Moli-sani project. A sample only including healthy women (5824) and men (5848) was analyzed. TAC was measured in foods by three different assays and the ferric reducing-antioxidant power (FRAP) assay was selected as the better indicator of dietary TAC. The European Investigation into Cancer and Nutrition Food Frequency Questionnaire was used for dietary assessment. The association between quintiles of dietary FRAP and pulmonary indexes was assessed using analysis of variance separately for men and women. Results: After adjustment for confounders, women in the highest quintile of FRAP intake had þ 39 ml forced expiratory volume in the first second (FEV 1 ) and þ 54 ml forced vital capacity, compared with those in the lowest quintile (P for trend p0.006). Stratified analysis showed that this relationship only occurred in women who were premenopausal/never smokers. In this subgroup, the observed effect of higher FRAP intake on FEV 1 was equivalent to an improvement in pulmonary age of 3.3 years. In men, all significant associations between pulmonary function and TAC were lost after adjustment for confounding. Conclusions: Dietary TAC may have a favorable role in respiratory health, particularly in premenopausal/never smoker women.

show abstract

General considerations for lung function testing

Cited by 1,708 publications

References 84 publications

A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD

A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD

Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study

Total dietary antioxidant capacity and lung function in an Italian population: a favorable role in premenopausal/never smoker women

Contact Info

Product

Resources

About